Drug intelligence / Profile preview

The NO.1 Xiaoqian Prescription

Development stage: Preclinical
Lead developer: Xiyuan Hospital

Overview

The NO.1 Xiaoqian Prescription is a traditional Chinese medicine (TCM) formulation developed by Xiyuan Hospital, China Academy of Chinese Medical Sciences, and supported by the Science and Technology Innovation Project of China Academy of Chinese Medical Sciences. It is currently undergoing clinical evaluation for its efficacy in the prevention and treatment of children with 'high-risk wheezing' and 'pre-asthma lesions', with Montelukast serving as a control in trials. As a prescription, it is understood to be a combination of multiple active ingredients, typical of TCMs.

Other names: Xiaoqian哮前1号方

Beyond the preview

Go deeper on The NO.1 Xiaoqian Prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The NO.1 Xiaoqian Prescription.

Explore the full profile